Matt Landry
Nurse Practitioner · Lafayette, LANPI 1861766206
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,500 of the $50,416 with a category attached, or 76.4%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 84.7% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $14,583 and has fallen 74.3% since, to $3,744 in 2025. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 340 payments — averaging $148.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$43K
- Abiomed$3K
- Silk Road Medical, Inc.$708
- Amgen$583
- Boehringer Ingelheim$441
- Abbott$440
- plus $3K from 21 others
What the payments were for
- Speaking & faculty fees$38,50076%
- Travel & lodging$8632%
- Food & beverage$11,05322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 138 | $42,722 |
| Abiomed | 46 | $2,635 |
| Silk Road Medical, Inc. | 11 | $708 |
| Amgen | 25 | $583 |
| Boehringer Ingelheim | 8 | $441 |
| Abbott | 9 | $440 |
| Pfizer | 22 | $428 |
| AstraZeneca | 19 | $401 |
| Atricure, Inc. | 6 | $316 |
| Boston Scientific | 4 | $250 |
| Kestra Medical Technology Services, Inc. | 3 | $225 |
| E.r. Squibb & Sons, L.L.C. | 8 | $185 |
| Inari Medical, Inc. | 1 | $160 |
| Bard Peripheral Vascular, Inc. | 1 | $152 |
| Novartis | 18 | $145 |
| Penumbra, Inc. | 1 | $135 |
| Esperion Therapeutics, Inc. | 1 | $124 |
| Johnson & Johnson | 4 | $70 |
| Astellas Pharma US Inc | 4 | $65 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $62 |
| Medtronic | 2 | $50 |
| Philips North America LLC | 1 | $28 |
| ALON Medical Technology | 1 | $24 |
| Merck | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Itamar Medical Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$38,900
- Impella$1,261
- ENROUTE Transcarotid Neuroprotection System$379
- JARDIANCE$345
- FLOWTRIEVER CATHETER, S$321
- ENROUTE Transcarotid Stent$276
- SYNERGY ABLATION SYSTEM$180
- Venclose Maven Catheter$152
- Assure WCD$151
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$150
- Indigo System$135
- NEXLIZET$124
- NEXLETOL$124
- CARDIOMEMS$119
- Repatha$108
- CAMZYOS$108
How this compares
$50,416 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $17,553 |
| EntrestoSacubitril/Valsartan | 15 | $13,765 |
| FarxigaDapagliflozin Propanediol | 14 | $9,473 |
| BrilintaTicagrelor | 15 | $7,258 |
| Metoprolol Succinate | 56 | $619 |
| ClopidogrelClopidogrel Bisulfate | 63 | $551 |
| Midodrine Hcl | 11 | $533 |
| Atorvastatin Calcium | 33 | $278 |
| Valsartan | 14 | $242 |
| Nitroglycerin | 12 | $216 |
| Pantoprazole Sodium | 16 | $200 |
| Potassium Chloride | 11 | $69 |
| Metoprolol Tartrate | 21 | $63 |
| Carvedilol | 14 | $48 |
| Furosemide | 20 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $428 | $17,55329 claims |
| AstraZenecaFarxiga, Brilinta | $401 | $16,73129 claims |
| NovartisEntresto | $145 | $13,76515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in Lafayette
- Karen DeshotelLafayette$264K
- Cynthia CobbLafayette$48K
- Mareesa MathersLafayette$10K
- Paula MitchellLafayette$8K
- Andre KnappLafayette$8K
- Emily LevyLafayette$8K
- Craig ManzerLafayette$7K
- Kellie WestLafayette$7K
- Courtney LafleurLafayette$6K
- Christopher ManuelKaplan$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.